3,464 Shares in Danaher Corporation $DHR Purchased by SCS Capital Management LLC

Key Points

• SCS Capital Management LLC acquired 3,464 shares of Danaher Corporation valued at approximately $711,000 during the first quarter, further increasing the interest shown by multiple hedge funds in the stock.
• Insider activity includes Director Teri List selling 2,778 shares for approximately $586,325, representing an 11.81% decrease in her holdings.
• Several analysts have recently upgraded their ratings on Danaher, with a consensus rating of "Moderate Buy" and an average target price of $246.35, indicating positive sentiment towards the stock's performance.

SCS Capital Management LLC acquired a new position in shares of Danaher Corporation (NYSE:DHR - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 3,464 shares of the conglomerate's stock, valued at approximately $711,000.

Several other hedge funds have also bought and sold shares of DHR. Nuveen LLC bought a new stake in Danaher during the first quarter worth about $833,941,000. GAMMA Investing LLC boosted its stake in Danaher by 24,958.2% during the first quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate's stock worth $383,524,000 after acquiring an additional 1,863,381 shares in the last quarter. Two Sigma Advisers LP boosted its stake in Danaher by 4,248.8% during the fourth quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate's stock worth $376,347,000 after acquiring an additional 1,601,800 shares in the last quarter. Invesco Ltd. boosted its stake in Danaher by 44.5% in the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock worth $965,259,000 after purchasing an additional 1,450,703 shares in the last quarter. Finally, Point72 Asset Management L.P. increased its stake in Danaher by 460.6% during the 4th quarter. Point72 Asset Management L.P. now owns 1,348,544 shares of the conglomerate's stock valued at $309,558,000 after purchasing an additional 1,107,998 shares in the last quarter. Institutional investors own 79.05% of the company's stock.

Insider Activity at Danaher

In other news, Director Teri List sold 2,778 shares of the company's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director owned 20,751 shares of the company's stock, valued at $4,379,706.06. This represents a 11.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 11.10% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on DHR. Robert W. Baird upped their target price on shares of Danaher from $225.00 to $226.00 and gave the stock an "outperform" rating in a research note on Friday, July 18th. Wall Street Zen upgraded shares of Danaher from a "hold" rating to a "buy" rating in a report on Friday, June 27th. Royal Bank Of Canada set a $241.00 price target on shares of Danaher in a report on Tuesday, September 2nd. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Finally, Scotiabank raised shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target on the stock in a report on Friday, July 11th. Seventeen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $246.35.

Danaher Price Performance

NYSE DHR opened at $192.85 on Thursday. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $279.90. The firm has a market capitalization of $138.09 billion, a P/E ratio of 41.03, a PEG ratio of 2.71 and a beta of 0.75. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The company has a 50-day moving average price of $201.62 and a 200-day moving average price of $199.15.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. During the same quarter in the prior year, the firm earned $1.72 EPS. The business's revenue for the quarter was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities research analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be given a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.7%. Danaher's dividend payout ratio is presently 27.23%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.